GlobalData on MSN5 天
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
pharmaphorum1 天
BMS gets FDA OK for first LAG-3 checkpoint inhibitor
The US regulator cleared BMS' LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with ...
pharmaphorum3 天
AstraZeneca gets first okay for CTLA4 drug tremelimumab
The CTLA4 inhibitor – now given the brand name Imjudo – is only the ... which is used alongside BMS' PD-1 inhibitor Opdivo (nivolumab) in several solid tumours, including HCC and lung ...
ascopubs.org4 天
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living ...
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...